Azithromycin · Azasite, Zithromax

What is Azithromycin?

Azithromycin is a macrolide antibacterial that binds the 23S rRNA of the bacterial 50S ribosomal subunit, inhibiting protein synthesis. It is also studied in non-tuberculous mycobacterial infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Azasite, Zithromax, Azithromcyin

Drug type

Small molecule

Targets

bacterial 23S rRNA

Mechanism

Inhibitor of bacterial 23S rRNA

Pathways

bacterial protein synthesis inhibition

Therapy area

Infectious disease

Developer

Pfizer

In trials of

INVA

FDA status

Approved as Azasite, Zithromax (November 1, 1991), NDA050670 · FDA label

✅ FDA-approved uses

• Acute bacterial exacerbations of chronic bronchitis (Zithromax)
• Acute bacterial sinusitis (Zithromax)
• Uncomplicated skin and skin structure infections (Zithromax)
• Urethritis and cervicitis (Zithromax)
• Genital ulcer disease (Zithromax)
• Acute otitis media (Zithromax)
• Community-acquired pneumonia (Zithromax)
• Pharyngitis/tonsillitis (Zithromax)

From the indications section of the FDA label (version of Jul 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) Infections

Sources

• FDA label (DailyMed)
• FDA label Zithromax (2026-07-24), indications
• FDA label Azasite (2024-07-25), indications
• ClinicalTrials.gov NCT07485010

Updated Oct 3, 2026.